Semler Scientific Earnings Preview
Semler Scientific (SMLR) is gearing up for its upcoming quarterly earnings announcement, sparking curiosity among investors. As a pivotal moment for the company, understanding the expectations surrounding this release is essential.
Earnings Expectations
There's a buzz in the investment community as analysts predict Semler Scientific will report an earnings per share (EPS) of $-0.27. Despite the negative outlook, anticipation for the earnings report remains high, with many hoping for more than just meeting estimates.
Analyzing Market Sentiment
For new investors, it is crucial to grasp that while earnings reports can significantly influence stock prices, it’s often the forward guidance that drives market reactions. Investors are keenly interested in Semler Scientific's projections for the next quarter.
Historical Performance Insights
A closer look at Semler Scientific’s earnings history reveals fluctuations in EPS and resulting stock price changes:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.20 | 0.37 | 0.56 | |
| EPS Actual | -6.74 | 3.41 | 0.72 | 0 |
| Price Change % | -11.0% | 3.0% | 30.0% | 5.0% |
Current Market Performance
As of the end of July, Semler Scientific's shares were trading at $35.85, showcasing a robust increase of 32.47% over the past year. This positive trend may comfort long-term investors heading into the earnings release.
Expert Opinions and Analyst Ratings
Understanding market sentiment is vital for investors. Analysts currently rate Semler Scientific with a consensus rating of Buy, projecting an average one-year price target of $85.67, indicating a remarkable potential upside of 138.97%.
Comparative Analysis with Peers
To gain a better understanding of Semler Scientific's positioning, let’s compare it with some reputable peers in the healthcare market.
- ZimVie has a Neutral rating, with a price target forecast of $14.5.
- Orthofix Medical is rated Outperform, targeting $16.0.
- Butterfly Network has a Buy rating, set at $3.5.
Understanding the Peer Landscape
This peer analysis reveals key metrics that shed light on Semler Scientific's performance versus industry competitors, thereby aiding investors in evaluating their market strategy.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Semler Scientific | Buy | -44.44% | $7.90M | -32.97% |
| ZimVie | Neutral | -0.13% | $75.31M | -0.98% |
| Orthofix Medical | Outperform | 2.67% | $121.62M | -11.04% |
| Butterfly Network | Buy | 20.21% | $13.38M | -6.84% |
Despite the overall positive sentiment, Semler Scientific faces hurdles. It ranks low in revenue growth and gross profit compared to its peers, which could raise concerns among stakeholders.
Company Insight
Semler Scientific Inc specializes in technology solutions aimed at enhancing healthcare efficacy. They develop and market innovative products that assist healthcare providers in assessing and treating chronic diseases, predominantly through their QuantaFlo brand, a state-of-the-art vascular-testing product.
Financial Performance Deep-Dive
Market Capitalization Context: The market cap of Semler Scientific indicates it operates on a smaller scale than many of its competitors, which might stem from growth potential perceptions.
Revenue Growth Challenges: The company’s latest earnings reports indicated a substantial decline of -44.44% in revenue growth.
Profitability Concerns: Semler's net margin stands at -732.34%, suggesting significant challenges in maintaining profitability. The return on equity is also concerning, at -32.97%.
Debt Management: The company's debt-to-equity ratio sits below industry averages at 0.59, indicating prudent debt management despite overall performance issues.
Frequently Asked Questions
What earnings per share is Semler Scientific expected to report?
Semler Scientific is expected to report an earnings per share (EPS) of $-0.27.
How have Semler Scientific's shares performed in the last year?
Semler Scientific shares have increased by 32.47% over the last 52 weeks.
What is the analyst consensus for Semler Scientific?
Analysts hold a consensus rating of Buy for Semler Scientific.
How does Semler Scientific's financial performance compare to its peers?
Semler ranks lower in revenue growth and gross profit compared to competitors like ZimVie and Orthofix Medical.
What core product does Semler Scientific offer?
Semler Scientific markets its QuantaFlo brand, which provides a vascular-testing solution for healthcare providers.
